For example, the combination of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), with nivolumab, an anti-PD-1 antibody, has been evaluated clinically in advanced NSCLC patients with EGFR mutations [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.